PRKAA1 and central nervous system cancer: Interestingly, when AMPK and PPAR scores were collectively used for patient stratification, we found that patients with low AMPK and high PPAR scores had the highest death rates (HR = 11.308, P < 0.0001), confirming that PPAR hyperactivation is associated with poor outcomes in glioma tumors with low AMPK activity [19] (Fig. 7).